Magnesium Sulfate Kalceks (Magnesium Sulfate Heptahydrate)

Magnesium sulfate works by antagonizing calcium at voltage‑gated channels, blocking NMDA receptors, and causing vasodilation. These actions reduce neuronal excitability, stabilize cardiac membranes, and relax smooth muscle, which together help control seizures, correct arrhythmias, and improve airway tone during severe bronchospasm.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goals. Dosing regimens vary for obstetric emergencies, cardiac arrhythmias, or magnesium deficiency, and should follow local clinical guidelines.

Magnesium sulfate is commonly used in pregnancy for eclampsia and preeclampsia when the benefits outweigh potential risks. Safety data for breastfeeding are limited, but small amounts may be excreted in milk. Clinicians should evaluate each case individually and follow obstetric recommendations.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Magnesium Sulfate Kalceks is an injectable formulation, offering rapid systemic availability compared with oral magnesium salts, which have slower absorption and gastrointestinal side effects. Compared with calcium gluconate, magnesium provides direct anticonvulsant and anti‑arrhythmic effects, though both may be used together in specific cardiac protocols.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the vial for particulate matter or discoloration, and allow it to reach room temperature if required for injection, following aseptic technique.

Administration is performed by a qualified health professional via intramuscular, intravenous, or subcutaneous injection. The route and infusion speed are chosen according to the clinical indication, with careful monitoring of vital signs and serum magnesium levels during and after administration.

Serious risks include respiratory depression, severe hypotension, cardiac arrest, and hypermagnesemia leading to loss of deep tendon reflexes or cardiac conduction disturbances. Prompt recognition of these signs and immediate medical intervention are essential.

Patients with known hypersensitivity to magnesium sulfate, severe renal failure without dialysis, existing heart block, or uncontrolled myasthenia gravis should avoid this product unless a specialist determines that benefits outweigh risks.